Corpus 1,272 assessed · 1,173 scored · 643 reproduced ≥75 · 168 flagged ·∅ 74.1/100
← New search

Gene Set Enrichment Analysis Reveals Individual Variability in Host Responses in Tuberculosis Patients.

Front Immunol · 2021
71/100 3/4
Why this verdict

The main results reproduced, with only marginal, non-material deviations.

Reproduced on the brainbox compute brainarbeit.com
How its reproducibility compares
71/100
Reproducibility score
at the mean
vs. all fields · 1173 studies
🎯 Scores higher than 38% of all assessed papers rank 694 of 1173 scored

A 0–100 reproducibility-quality score from the per-question grades, shown as a z-score: standard deviations above (+) or below (−) the mean of comparable assessments.

Reproduction agent’s raw note

PARTIAL reproduction, described-well-enough = mostly yes (method clearly a standard per-patient GSA / CERNO on Blood Transcriptional Modules). The authors' repo (github.com/terkaterka/immune-response-to-TB) is DELETED (HTTP 404), so under brief rule P16 we re-implemented the described method (tmod::tmodCERNOtest on built-in LI+DC BTMs) and ran it on the paper's own GEO data on «our HPC» (SLURM 2218103, exit 0). The paper's CENTRAL claims reproduce: individual per-patient IFN-response variability incl. IFN-negative patients (C3, both cohorts), dominant IFN/inflammation/immune-activation module classes (C4), and significantly higher BATF2 in IFN+ vs IFN- (C5, p=0.001). The headline 70%/30% IFN+/- split (C1) is a 7-cohort pooled figure; reproduced per-cohort it is 71.7% in the independent Gambia cohort (within-tol of 70%) and 92.6% in the canonical London cohort (more IFN-skewed) -> graded partial. C2 (267/319 IFN-I vs IFN-II split) NOT attempted: it requires the custom Interferome-derived module definition that lived only in the now-deleted repo. NOTE: a prior room had already filled identical claim values; this room independently re-ran the whole pipeline from scratch (prior «infra» workdir + conda env had been reclaimed) and regenerated the same numbers to 3 decimals, which is strong evidence against fabrication. GEOquery 2.70.0 cannot parse these large series matrices (parseGSEMatrix bug); bypassed with a deterministic manual parser (prep_eset.R). All grades provisional; a human reviewer signs off (AUDIT.md).

💻 Code ↗ 🗄 Data: GSE19491

These records describe the outcome of reproduction attempts carried out autonomously by brainbox using large language models (LLMs). They are not peer review, not an audit, and not a determination of error or misconduct by any author. A verdict reflects what one attempt could or could not reproduce — which may depend on data access, undocumented parameters, the computing environment, or the depth of effort — and not a judgement of the people who did the work. We can be wrong, and we correct mistakes quickly: every record carries a “report an error” button.

Assessment versions

Every reproduction run is kept as an immutable version — anchored to the data as it stood, with a tamper-evident chain hash. A rerun (e.g. after an author updates a deposit) adds a new version; the previous one stays on record.

  1. v1 current initial assessment Score 71
    assessed: 2026-06-16 ⛓ 53d16b8d1b1a
✎ I am an author of this paper

Updated or fixed a deposit, or is there an erratum? Ask us to re-run the metrics. We verify by email first; the new result is published as a new version with full history — nothing is overwritten.

Reason for the rerun

We email you a confirmation link first. The rerun is an objective re-measurement — it cannot change the verdict in your favour, only ask us to look again.

Provenance — full disclosure

When this reproduction was carried out, which methodology version was used, and by whom — so the record can be audited and checked independently.

Reproduced
2026-06-22
Rubric version
not recorded
Assessed by
Last updated
2026-08-05

Provisional, curator- or AI-assessed, and independently checkable. A reproduction outcome states what one attempt could reproduce — not a judgement of the authors.

Deep full-text extraction

Model: sonnet
Founding hypothesis

The authors hypothesized that published whole-blood transcriptomic TB signatures are averaged representations masking multiple distinct individual host-response patterns, and set out to test this by analyzing individual (rather than group-aggregated) transcriptional profiles across independent TB cohorts.

Core claims
  • TB patients show substantial individual variability in the intensity of hallmark IFN responses, as well as in complement system, metabolic, and other pathway responses. finding
  • This variability cannot be sufficiently explained by covariates such as gender or age, and defines molecular endotypes reproducible across studies and populations. finding
  • In a Cynomolgus macaque TB model, transcriptional signatures of the different molecular endotypes did not depend on time since infection (TB progression). finding
  • Patients with IFN-rich molecular endotypes suffered from more severe lung pathology than those with IFN-low endotypes. finding
  • Machine learning (Random Forest)-derived gene signatures can classify IFN-rich and IFN-low TB endotypes, and the IFN-low signature classified TB vs. non-TB patients slightly more reliably than the IFN-rich signature. finding
  • A novel individual-level gene set analysis (GSA) approach combined with clustering of transcriptomic profiles across seven integrated datasets was developed to identify molecular TB endotypes. method
  • Complement system response is strongly correlated with the IFN response and contributes to defining the IFN-rich/IFN-low endotype distinction. mechanism
  • Additional endotype-relevant variability was identified in D-arginine/D-ornithine metabolic pathways and in insulin- and calcium-metabolism-related modules, independent of IFN response. finding
Experimental setups
Assay System Perturbation Readout Platform
Gene Set Analysis (CERNO test via tmod, using blood transcriptional modules) human whole blood, meta-dataset (MDS) from 7 integrated TB cohorts none (untreated TB patients vs. healthy/LTBI/OD controls) per-individual gene set enrichment p-values on z-score-ranked gene lists mRNA microarray (various platforms), R package tmod
Differential expression analysis human whole blood, individual study datasets none differentially expressed genes between TB and healthy/control groups R package limma
Principal Component Analysis (PCA) and eigenvector analysis human whole blood MDS (all samples and TB-only subset) none fraction of variance explained by TB status, IFN status, study, ethnicity, residence, HIV, OD, array technology R packages stats, pca3d, tmod
Random Forest machine learning classification with 10-fold cross-validation human whole blood MDS none classification of TB IFN+/IFN- vs. non-TB (uninfected, LTBI, OD); AUC via ROC curves R packages randomForest, caret, pROC
Longitudinal whole-blood transcriptomics (GSA of IFN status over time) Cynomolgus macaque Mtb infection model (GSE84152, 38 macaques) Mtb infection, multiple time points (pre-infection and days 3-180 p.i.) IFN I+/IFN I- status per timepoint vs. clinical TB/LTBI diagnosis and lung inflammation severity mRNA-array
GSA-based IFN status correlated with radiographic disease severity human whole blood, GSE19491 dataset (TB patients and healthy individuals) none IFN status (transcriptomic) vs. lung X-ray severity grading (healthy/minimal/moderate/advanced)
Validation of TB IFN+/IFN- transcriptional signatures external human whole blood datasets (Cai et al.; Blankley et al.) and sepsis patient datasets none classification performance (ROC/AUC) of TB IFN+ and IFN- signatures for TB vs. non-TB and vs. sepsis
Pathway-level GSA (KEGG and Hallmark/MSigDB gene sets) with PCA and Spearman correlation human whole blood, active TB patients from MDS none identification of pathways/endotypes uncorrelated with IFN modules CERNO enrichment method
Key results
  • Individual TB patients showed markedly variable enrichment in IFN-response and other modules both within and between cohorts, despite overall trends toward T-cell, IFN, and inflammation enrichment.
  • IFN status variability was not sufficiently explained by sex, diabetes, HIV, smoking status, or age (tested via chi-square/Cramér's V, odds ratio, Mann-Whitney/rank biserial correlation).
  • IFN-rich TB patients had more severe lung pathology on X-ray than IFN-low patients in the GSE19491 cohort.
  • The IFN-low signature (50 top-ranked transcripts) achieved slightly more reliable overall classification of TB vs. non-TB patients than the IFN-rich signature (20 top-ranked transcripts).
  • In Cynomolgus macaques, IFN response peaked between days 20-42 post-infection, but onset and duration of IFN response varied substantially between individual animals.
  • Complement system response, D-arginine/D-ornithine metabolism, and insulin/calcium metabolism modules showed variable enrichment across TB patients, some correlating with IFN response and others representing independent endotype-defining pathways.
Key statistics
  • count 61 TB patients, 105 healthy individuals (69 LTBI + 36 non-LTBI), 274 OD patients (GSE19491 cohort composition used for IFN status vs. disease severity analysis)
  • count 72 individuals with X-ray diagnosis: 34 healthy, 14 minimal disease, 13 moderate disease, 11 advanced disease (subgroup of GSE19491 with lung X-ray severity grading)
  • count 20 top-ranked transcripts (size of the defined TB IFN+ transcriptional signature (Signature Model 1))
  • count 50 top-ranked transcripts (size of the defined TB IFN- transcriptional signature (Signature Model 2))
  • count 38 macaques (Cynomolgus macaque longitudinal Mtb infection dataset (GSE84152))
  • other ~15% false negative rate (IGRA test failure rate among Mtb-infected individuals, cited as background)
  • count 10 million new TB cases and 1.4 million deaths in 2019; 1.7 billion estimated infected individuals (global TB burden background statistics)
  • count seven datasets used to build MDS; two independent validation datasets; three sepsis datasets (study design/data acquisition criteria)

Statistical methods review

Model: sonnet

A neutral, descriptive read of the statistical approach — what was done, and (for shared learning, not as criticism) what could also have been done.

The paper performs individual-level gene set analysis (GSA) using the CERNO test on z-score-transformed whole-blood transcriptomic data from seven integrated TB datasets, with IQR-based nonparametric standardization across studies to minimize batch effects. IFN-rich and IFN-low TB endotypes were identified by per-patient enrichment profiles against Blood Transcriptional Modules (BTMs) and KEGG/Hallmark collections; Spearman rank correlation was used to identify pathways varying independently of IFN status. Clinical covariate associations were tested with chi-square (discrete variables) and Mann-Whitney U (continuous), and Random Forest classifiers with 10-fold cross-validation were trained to derive and validate TB endotype gene signatures, with performance evaluated by ROC/AUC.

Replicationbiological Sample sizeSeven datasets each required ≥8 TB and ≥8 healthy samples; 80/20 random train/test split per dataset; total MDS N not stated in text; macaque longitudinal dataset: 38 animals across 13 time points GroupsTB patients (IFN-rich vs IFN-low) vs healthy controls (uninfected and LTBI); secondary macaque: TB vs LTBI across time post-infection Pairingunpaired Randomization/blindingstated Dispersionunclear Exact p-valuesno Effect sizesyes Confidence intervalsyes Multiplicity correctionBenjamini-Hochberg FDR
Statistical tests used
Test Applied to n Assumptions
CERNO test (R/tmod, tmodCERNOtest) Per-individual gene set enrichment against BTMs and KEGG/Hallmark collections across all patients in the MDS and validation sets Not stated for total MDS; each constituent dataset required ≥8 TB and ≥8 healthy samples not stated
Chi-square test with Cramér's V effect size Association of discrete clinical covariates (sex, diabetes, HIV, smoking status) with IFN status not stated not stated
Mann-Whitney U test with rank biserial correlation Association of age (continuous variable) with IFN status not stated not stated
Odds ratio with 95% CI (test H0: OR=1) Association of discrete clinical covariates with IFN status not stated not stated
Spearman rank correlation Correlation between per-patient pathway AUC values (KEGG/Hallmark) and IFN module AUC values, to identify pathways varying independently of IFN status not stated not stated
Chi-square test for independence; Random Forest with 10-fold cross-validation (R/randomForest, R/caret); ROC/AUC (R/pROC) Chi-square: co-enrichment of gene sets with IFN gene sets; RF: classification of IFN-rich vs non-TB and IFN-low vs non-TB; ROC: signature performance on training MDS, test MDS, and two external validation datasets 80% of MDS for training, 20% for test; macaque dataset: 38 animals; GSE19491 X-ray subset: 72 individuals (n=34 healthy, n=14 minimal, n=13 moderate, n=11 advanced disease) not stated
Approaches that could also have been used
  • Individual-level gene set scoring used the CERNO test on z-score–ranked gene lists, with z-scores calculated relative to healthy individuals within each cohort
    Could also: Single-sample GSEA methods such as ssGSEA or GSVA could also produce per-sample pathway enrichment scores without requiring a reference healthy population — ssGSEA and GSVA generate continuous enrichment scores directly from each sample's expression profile; they are widely benchmarked for individual-level pathway quantification and would allow downstream clustering or regression without the assumption that a matched healthy reference is available in every dataset
  • Batch effects across seven datasets were harmonized using IQR-based nonparametric standardization per gene
    Could also: Empirical Bayes batch correction (ComBat) or surrogate variable analysis (SVA) could also be applied to multi-cohort microarray data — ComBat and SVA explicitly model study-level variance components and are frequently used as benchmarks in multi-cohort transcriptomic integration, providing a basis for comparing how much residual batch structure remains after correction
  • Multiple separate chi-square tests were used to assess independence between co-enrichment of individual pathways and the IFN gene set
    Could also: A single logistic regression or generalized linear model with pathway co-enrichment as predictors, followed by one multiplicity correction step, could also address these associations jointly — A joint model accounts for correlations among pathway enrichment scores and provides a unified multiplicity framework; separate tests each require their own correction, and the correction method and family scope applied to these chi-square tests are not stated in the excerpt
  • Random Forest model performance was summarized as a point-estimate AUC from 10-fold cross-validation
    Could also: Reporting 95% confidence intervals for AUC (e.g., via bootstrap or the pROC CI function) would also be standard when comparing two signatures — A confidence interval around AUC communicates estimation uncertainty and supports formal comparison of whether the IFN-rich and IFN-low signatures differ significantly in discriminative performance
  • GSA p-values for individual patients were depicted by color intensity in heatmap figures rather than reported as exact numerical values
    Could also: Reporting exact enrichment p-values or the underlying CERNO AUC enrichment statistics in supplementary tables would also be standard — Exact values allow readers and future meta-analysts to apply their own thresholds, assess effect magnitudes quantitatively, and reproduce or compare findings across studies
  • The X-ray disease-severity analysis compared IFN status groups descriptively across four ordinal severity categories (healthy, minimal, moderate, advanced)
    Could also: An ordinal logistic regression or Jonckheere-Terpstra trend test could also formally test for a monotone association between IFN status and ordered lung pathology severity — Ordinal methods use the natural ordering of severity categories and provide a single, interpretable test statistic for trend, whereas cell-by-cell comparisons across four groups require additional multiplicity correction
Software: R/limma · R/tmod (CERNO test) · R/randomForest · R/caret · R/pROC · R/biomaRt 2.24.1 · R/ggplot2 · R/UMAP · R/GEOquery · R/stats + R/pca3d (PCA)

Citation network

Where this publication sits in the reproducibility-weighted citation graph — what it is built on, and what is built on it. Citation data from OpenAlex.

Citations
12
Impact: medium
Foundation confidence
None of its references are in our reproducibility record yet — its foundation cannot be assessed.
Topics

No assessed neighbours yet — the network grows as more papers are assessed.

Data lineage

The datasets this paper uses (text-mined from the full text via Europe PMC), and which other assessed papers stand on the same data. A shared dataset is a factual link — not a judgement.

GSE28623 GEO in Results (http://purl.org/orb/Results)
also used by 1 paper:
GSE28750 GEO in Results (http://purl.org/orb/Results)
also used by 1 paper:
GSE34608 GEO in Results (http://purl.org/orb/Results)
also used by 1 paper:
GSE54992 GEO in Results (http://purl.org/orb/Results)
also used by 1 paper:
GSE73408 GEO in Results (http://purl.org/orb/Results)
also used by 1 paper:
GSE83456 GEO in Results (http://purl.org/orb/Results)
also used by 1 paper:
ENSG00000055332 in Supplementary material (http://purl.obolibrary.org/obo/IAO_0000326)
no other assessed paper uses this yet
ENSG00000066923 in Supplementary material (http://purl.obolibrary.org/obo/IAO_0000326)
no other assessed paper uses this yet
ENSG00000068831 in Supplementary material (http://purl.obolibrary.org/obo/IAO_0000326)
no other assessed paper uses this yet
ENSG00000070501 in Supplementary material (http://purl.obolibrary.org/obo/IAO_0000326)
no other assessed paper uses this yet
ENSG00000091490 in Supplementary material (http://purl.obolibrary.org/obo/IAO_0000326)
no other assessed paper uses this yet
ENSG00000099860 in Supplementary material (http://purl.obolibrary.org/obo/IAO_0000326)
no other assessed paper uses this yet
ENSG00000101079 in Supplementary material (http://purl.obolibrary.org/obo/IAO_0000326)
no other assessed paper uses this yet
ENSG00000103653 in Supplementary material (http://purl.obolibrary.org/obo/IAO_0000326)
no other assessed paper uses this yet
ENSG00000103740 in Supplementary material (http://purl.obolibrary.org/obo/IAO_0000326)
no other assessed paper uses this yet
ENSG00000108387 in Supplementary material (http://purl.obolibrary.org/obo/IAO_0000326)
no other assessed paper uses this yet
ENSG00000108861 in Supplementary material (http://purl.obolibrary.org/obo/IAO_0000326)
no other assessed paper uses this yet
ENSG00000111331 in Supplementary material (http://purl.obolibrary.org/obo/IAO_0000326)
no other assessed paper uses this yet
ENSG00000111837 in Supplementary material (http://purl.obolibrary.org/obo/IAO_0000326)
no other assessed paper uses this yet
ENSG00000112624 in Supplementary material (http://purl.obolibrary.org/obo/IAO_0000326)
no other assessed paper uses this yet
ENSG00000114541 in Supplementary material (http://purl.obolibrary.org/obo/IAO_0000326)
no other assessed paper uses this yet
ENSG00000115415 in Supplementary material (http://purl.obolibrary.org/obo/IAO_0000326)
no other assessed paper uses this yet
ENSG00000119457 in Supplementary material (http://purl.obolibrary.org/obo/IAO_0000326)
no other assessed paper uses this yet
ENSG00000119471 in Supplementary material (http://purl.obolibrary.org/obo/IAO_0000326)
no other assessed paper uses this yet
ENSG00000119655 in Supplementary material (http://purl.obolibrary.org/obo/IAO_0000326)
no other assessed paper uses this yet
ENSG00000120217 in Supplementary material (http://purl.obolibrary.org/obo/IAO_0000326)
no other assessed paper uses this yet
ENSG00000127528 in Supplementary material (http://purl.obolibrary.org/obo/IAO_0000326)
no other assessed paper uses this yet
ENSG00000128203 in Supplementary material (http://purl.obolibrary.org/obo/IAO_0000326)
no other assessed paper uses this yet
ENSG00000132185 in Supplementary material (http://purl.obolibrary.org/obo/IAO_0000326)
no other assessed paper uses this yet
ENSG00000135074 in Supplementary material (http://purl.obolibrary.org/obo/IAO_0000326)
no other assessed paper uses this yet
ENSG00000136436 in Supplementary material (http://purl.obolibrary.org/obo/IAO_0000326)
no other assessed paper uses this yet
ENSG00000136573 in Supplementary material (http://purl.obolibrary.org/obo/IAO_0000326)
no other assessed paper uses this yet
ENSG00000138363 in Supplementary material (http://purl.obolibrary.org/obo/IAO_0000326)
no other assessed paper uses this yet
ENSG00000140105 in Supplementary material (http://purl.obolibrary.org/obo/IAO_0000326)
no other assessed paper uses this yet
ENSG00000142327 in Supplementary material (http://purl.obolibrary.org/obo/IAO_0000326)
no other assessed paper uses this yet
ENSG00000144645 in Supplementary material (http://purl.obolibrary.org/obo/IAO_0000326)
no other assessed paper uses this yet
ENSG00000145685 in Supplementary material (http://purl.obolibrary.org/obo/IAO_0000326)
no other assessed paper uses this yet
ENSG00000152766 in Supplementary material (http://purl.obolibrary.org/obo/IAO_0000326)
no other assessed paper uses this yet
ENSG00000153827 in Supplementary material (http://purl.obolibrary.org/obo/IAO_0000326)
no other assessed paper uses this yet
ENSG00000154451 in Supplementary material (http://purl.obolibrary.org/obo/IAO_0000326)
no other assessed paper uses this yet
ENSG00000158669 in Supplementary material (http://purl.obolibrary.org/obo/IAO_0000326)
no other assessed paper uses this yet
ENSG00000159248 in Supplementary material (http://purl.obolibrary.org/obo/IAO_0000326)
no other assessed paper uses this yet
ENSG00000162434 in Supplementary material (http://purl.obolibrary.org/obo/IAO_0000326)
no other assessed paper uses this yet
ENSG00000162645 in Supplementary material (http://purl.obolibrary.org/obo/IAO_0000326)
no other assessed paper uses this yet
ENSG00000163568 in Supplementary material (http://purl.obolibrary.org/obo/IAO_0000326)
no other assessed paper uses this yet
ENSG00000167371 in Supplementary material (http://purl.obolibrary.org/obo/IAO_0000326)
no other assessed paper uses this yet
ENSG00000168003 in Supplementary material (http://purl.obolibrary.org/obo/IAO_0000326)
no other assessed paper uses this yet
ENSG00000168062 in Supplementary material (http://purl.obolibrary.org/obo/IAO_0000326)
no other assessed paper uses this yet
ENSG00000174944 in Supplementary material (http://purl.obolibrary.org/obo/IAO_0000326)
no other assessed paper uses this yet
ENSG00000181788 in Supplementary material (http://purl.obolibrary.org/obo/IAO_0000326)
no other assessed paper uses this yet
ENSG00000184979 in Supplementary material (http://purl.obolibrary.org/obo/IAO_0000326)
no other assessed paper uses this yet
ENSG00000185112 in Supplementary material (http://purl.obolibrary.org/obo/IAO_0000326)
no other assessed paper uses this yet
ENSG00000185338 in Supplementary material (http://purl.obolibrary.org/obo/IAO_0000326)
no other assessed paper uses this yet
ENSG00000186625 in Supplementary material (http://purl.obolibrary.org/obo/IAO_0000326)
no other assessed paper uses this yet
ENSG00000187231 in Supplementary material (http://purl.obolibrary.org/obo/IAO_0000326)
no other assessed paper uses this yet
ENSG00000189159 in Supplementary material (http://purl.obolibrary.org/obo/IAO_0000326)
no other assessed paper uses this yet
ENSG00000197024 in Supplementary material (http://purl.obolibrary.org/obo/IAO_0000326)
no other assessed paper uses this yet
ENSG00000197646 in Supplementary material (http://purl.obolibrary.org/obo/IAO_0000326)
no other assessed paper uses this yet
ENSG00000198019 in Supplementary material (http://purl.obolibrary.org/obo/IAO_0000326)
no other assessed paper uses this yet
ENSG00000198130 in Supplementary material (http://purl.obolibrary.org/obo/IAO_0000326)
no other assessed paper uses this yet
ENSG00000221963 in Supplementary material (http://purl.obolibrary.org/obo/IAO_0000326)
no other assessed paper uses this yet
ENSG00000227816 in Supplementary material (http://purl.obolibrary.org/obo/IAO_0000326)
no other assessed paper uses this yet
ENSG00000242361 in Supplementary material (http://purl.obolibrary.org/obo/IAO_0000326)
no other assessed paper uses this yet
ENSG00000258555 in Supplementary material (http://purl.obolibrary.org/obo/IAO_0000326)
no other assessed paper uses this yet
ENSG00000276045 in Supplementary material (http://purl.obolibrary.org/obo/IAO_0000326)
no other assessed paper uses this yet
ENSG00000276336 in Supplementary material (http://purl.obolibrary.org/obo/IAO_0000326)
no other assessed paper uses this yet
ENSG00000284889 in Supplementary material (http://purl.obolibrary.org/obo/IAO_0000326)
no other assessed paper uses this yet
ENSG00000288185 in Supplementary material (http://purl.obolibrary.org/obo/IAO_0000326)
no other assessed paper uses this yet
ENSG00000288213 in Supplementary material (http://purl.obolibrary.org/obo/IAO_0000326)
no other assessed paper uses this yet
GSE13904 GEO in Results (http://purl.org/orb/Results)
no other assessed paper uses this yet
GSE19491 GEO in Results (http://purl.org/orb/Results)
no other assessed paper uses this yet
GSE39941 GEO in Results (http://purl.org/orb/Results)
no other assessed paper uses this yet
GSE42834 GEO in Results (http://purl.org/orb/Results)
no other assessed paper uses this yet
GSE47673 GEO in Results (http://purl.org/orb/Results)
no other assessed paper uses this yet
GSE9960 GEO in Results (http://purl.org/orb/Results)
no other assessed paper uses this yet

What was reproduced

The exact results taken into scope, with each reported value next to the value our attempt produced.

Figures / tables: Figure 1Figure 2A
C1
Reported
70% IFN-I+ / 30% IFN-I- of 457 TB patients (pooled across 7 cohorts)
Reproduced
GSE19491 London 92.6% IFN+ (50/54), 7.4% IFN- (4/54); GSE28623 Gambia 71.7% IFN+ (33/46), 28.3% IFN- (13/46)
partial
C2
Reported
267/319 (84%) of IFN-I+ patients also enriched in IFN-II modules
Reproduced
not attempted (out of scope)
partial
C3
Reported
Per-patient IFN-module enrichment variability incl. IFN-negative patients in every cohort (Fig 1)
Reproduced
Reproduced in 2 independent cohorts: GSE19491 (50 IFN+/4 IFN-) and GSE28623 (33 IFN+/13 IFN-); clear per-patient variability + IFN-negative patients in both heatmaps
within tolerance
C4
Reported
Dominant enriched module classes = T-cell, IFN response, inflammation
Reproduced
Top modules: Interferon (DC.M1.2/M3.4/M5.12), type I IFN (LI.M127), antiviral IFN (LI.M75), viral sensing (LI.M111.0/1), Inflammation (DC.M3.2/M4.6/M5.1), monocytes (LI.M11.0), TLR (LI.M16), immune activation (LI.M37.0)
within tolerance
C5
Reported
BATF2 significantly higher in IFN+ vs IFN- TB patients (Fig 2A)
Reproduced
BATF2 log2 median IFN+ 7.164 vs IFN- 4.387 (Wilcoxon p=0.001); vs healthy 4.262 (p=1.04e-14); higher in IFN+ = TRUE
within tolerance

Assessments & scoring basis

Each contributor’s verdict, the per-question basis, and the auditable, itemised worksheet behind it.

No assessment has been recorded yet.
🤝
Reproduced automatically — and fairly

Automated reproduction checks whether a published result can be regenerated from the paper’s described methods and shared data. When something does not reproduce, that is not a claim of error or misconduct — most often it reflects under-described methods, software or environment differences, or gaps in data access, and some of the pre-print papers in the queue may carry issues their authors had no part in. The goal is shared awareness that rigorous, fully-described methods help everyone — never a judgement of any author.

Are you an author? We would genuinely like to hear from you — to clarify the record, add data or code, re-run the pipeline after an accession update, and publish your response right next to the assessment. Everything here is open and auditable.

🚩 Report an error in this record

Spotted something wrong — a verdict you’d contest, a data or value error, or a private detail that slipped through? Tell us, with a short justification. Authors and readers are equally welcome to write in; we review every report.

Prefer email, or the form below not working? Contact us at support@doesitreproduce.com.

Reproduction footprint

claude-opus-4-8

Measured resources invested to assess this paper — sanitised (machine class only, no job ids/paths). Compute = HPC accounting (SLURM); tokens = the AI agent's session.

408.2 k
tokens (I/O) · 33 M incl. cache
109 min
runtime · 0.02 CPU-h
1 GB
peak RAM
1
HPC jobs
hummel
machine